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Summary We determined nuclear DNA content from 308 archival paraffin-embedded malignant breast
tumours and evaluated the survival of the patients by univariate and multivariate statistical analyses. The
overall 8-year survival rate of stage I-III breast cancer patients was 74.3% in DNA-diploid and 51.2% in
DNA-aneuploid tumours (P<0.0001). DNA ploidy had prognostic significance in both node-negative and
node-positive breast cancer, primarily in cases with steroid receptor-positive tumours. In a Cox multivariate
analysis DNA ploidy (P=0.001), primary tumour size (P=0.0007), nodal status (P=0.04) and the content of
progesterone receptors (P=0.0008) emerged as significant independent prognostic factors, whereas oestrogen
receptor status, age and menopausal status of the patients had no significant independent prognostic value. If
the histological grade of ductal carcinomas was also included in the Cox model, both grade and DNA ploidy
had independent prognostic effect. In conclusion, our results indicate that the analysis of DNA ploidy is a
useful adjunct in the assessment of prognosis for breast cancer patients.
Recent reports have suggested that in breast cancer DNA
aneuploid tumours are associated with a shorter disease-free
interval (Hedley et al., 1984; Cornelisse et al., 1987; Dowle et
al., 1987; Kallioniemi et al., 1987a) and overall survival
(Coulson et al., 1984; Cornelisse et al., 1987; Dowle et al.,
1987) than DNA diploid tumours. DNA aneuploidy has
been shown to be associated with several other prognostic
parameters such as the age and menopausal status of the
patients (Taylor et al., 1983; Dowle et al., 1987), primary
tumour size (Ewers et al., 1984; Cornelisse et al., 1987;
Dowle et al., 1987), nodal status (Hedley et al., 1984;
Cornelisse et al., 1987), grade of the tumour (Moran et al.,
1984; McDivitt et al., 1986; Dowle et al., 1987; Kallioniemi
et al., 1987a) and the content of oestrogen and progesterone
receptors (Bichel et al., 1982; Moran et al., 1984; Coulson et
al., 1984; Horsfall et al., 1986; Kallioniemi et al., 1987a).
Whether DNA ploidy is an independent prognostic indicator
or merely related to other prognostic factors is unclear
(McGuire & Dressler, 1985; Cornelisse et al., 1987; Dowle et
al., 1987).
In the present study we evaluated the clinicopathological
correlations and prognostic value of DNA ploidy in 308
breast cancer patients. DNA flow cytometric analysis was
carried out on archival paraffin-embedded tumour samples.
The prognostic value of DNA ploidy was evaluated in
subgroups of patients defined by other prognostic factors.
The Cox proportional hazards regression model was also
used in evaluating the independence of DNA ploidy as a
prognostic factor.
Materials and methods
Patients
Consecutive patients operated on for primary breast cancer
in the Oulu University Central Hospital in 1975-1980 (169
cases) and in the Tampere University Central Hospital in
1977-1982 (139 cases) were included in the study. The study
group comprises a part of a previous larger multicenter
study on steroid receptor assays in breast cancer (Blanco et
al., 1984). All patients for whom histological slides and
tissue blocks were available were included in the study. For
the majority of cases clinical follow-up was extended to
January 1984 and for about 100 patients up to December
1986. Fifteen cases had to be excluded from the study due to
the inability to obtain good DNA histograms from the
tumors. The clinicopathological features of the 308 cases are
shown in Table I.
Primary tumour size and axillary node involvement were
determined according to the TNM classification. The nodal
involvement was in all cases verified histologically, whereas
determination of the extent of node involvement was based
on clinical examination. The histology of the tumours was
reviewed independently by two pathologists, who classified
and graded the tumours according to the WHO classification
of breast tumours (Scarff & Torloni, 1968). During the
operation a small tumour sample was frozen in liquid
nitrogen for steroid receptor assays, which were done by the
dextran charcoal method in the Department of Clinical
Chemistry, Oulu University Central Hospital, as previously
described (Vihko et al., 1980). Both oestrogen and
progesterone receptor assays were available for 306 patients.
The primary treatment was simple mastectomy in 100
cases and mastectomy with axillary evacuation in 198 cases.
Three patients with stage I cancer were treated by simple
excision alone, whereas two patients with advanced
metastatic disease were treated with extended radical
mastectomy (Halsted). Five cases were considered
inoperable. Postoperative radiotherapy was given to 203
patients, mainly in cases with involved axillary nodes.
Adjuvant cytotoxic CMF chemotherapy was given to 48
patients, most of them having stage II disease. The patients
were seen at 2-3 month intervals for one year, at 3-4 month
intervals for 3 years and annually thereafter. Whenever
possible, metastases were verified either cytologically or
histologically. Patients with metastases were given hormone
therapy if the primary tumour was steroid receptor positive
and cytotoxic chemotherapy in cases of receptor negative
tumours.
DNAflow cytometry
Paraffin-embedded tumours were processed for DNA flow
cytometry by a previously described modification
(Kallioniemi et al., 1987a) of the method of Hedley and
coworkers (Hedley et al., 1983). Briefly, 50jgm sections from
the paraffin-embedded tumours were dewaxed with xylene,
rehydrated and digested overnight with trypsin. One to 6
sections from different parts of the primary tumour were
processed for DNA flow cytometry. The nuclear suspension
was stained with ethidium bromide, digested with RNAase
and analysed with an EPICS C flow cytometer using 488 nm
excitation. DNA index of aneuploid peaks and the
coefficient of variation (CV) of all DNA peaks were
Correspondence: O.-P. Kallioniemi.
Received 27 May 1987; and in revised form, 11 August 1987.
Br. J. Cancer (1987), 56, 637-642 The Macmillan Press Ltd., 1987638 O.-P. KALLIONIEMI et al.
calculated with the STATPACK program of the instrument.
Mean CV of the diploid DNA peak was 5.50 (range 2.8-7.0),
which usually allowed the detection of DNA peaks with a
DNA index greater than 1.15. Nine diploid tumours with CV
over 7.0% and 6 samples with excessive debris were not
included in the study.
Statistical analyses
All the clinicopathological parameters as well as the results
from DNA flow cytometry were processed with a DEC 2060
Computer of the University of Tampere Computer Centre
using the BMDP Statistical Software Package (Dixon, 1983).
Actuarial survival curves of patients were calculated using
the BMDPIL programme. The significance of survival
differences between DNA-diploid and DNA-aneuploid cases
was calculated by Wilcoxon-Breslow and Mantel-Cox
statistics. The Cox proportional hazards model (Cox, 1972)
was used in multivariate analyses of the survival data
(BMDP2L). The validity of the proportional hazard
assumption was verified by plots of the log minus log
survival function.
Results
There was a significant association between DNA
aneuploidy and poor differentiation state of the tumour
(P=0.003) as well as between DNA aneuploidy and lack of
progesterone receptors (P=0.0006) (Table I). A definite but
Table I Clinicopathological features in 308 cases of breast cancer.
Relation to DNA ploidy
No ofcases DNA-aneuploid
(percentage) no./total (%)
All patients 308 196/308 (63.6%)
Age
<50 107 (34.7%) 63/107 (58.9%) x2= 8.30
50-65 97 (31.5%) 73/97 (75.3%) P=0.02
>65 104 (33.8%) 60/104 (57.7%)
Premenopausal 107 (35.0%) 63/107 (58.9%) X2=1.60
Postmenopausal 201 (65.0%) 133/201 (66.2%) P=0.21
TNM-clatsification:
Ti 76 (24.7%) 45/76 (59.2%)
T2 165 (53.6%) 104/165 (63.0%) X2 1.54
T3 39 (12.7%) 26/39 (66.7%) P=0.67
T4 28 (9.1%) 20/28 (71.4%)
NO 165 (53.6%) 94/165 (57.0%)
N1 121 (39.3%) 82/121 (67.8%) X2 9.59
N2 16 (5.2%) 13/16 (81.3%) P 0.02
N3 6 (1.9%) 6/6 (100.0%)
MO 297 (96.4%) 185/297 (62.3%) x2=3.74
M1 1i (3.6%) 10/11 (90.9%) P= 0.05
Stage I 53 (17.2%) 27/53 (50.9%)
Stage II 175 (56.8%) 113/175 (64.6%) X2=6.95
Stage III 69 (22.4%) 46/69 (66.7%) P 0.07
Stage IV 11 (3.6%) 10/11 (90.9%)
Histology: Ductal
infiltrating
Grade I 40 (12.9%) 22/40 (55.0%) X2= 11.43
Grade II 111 (35.9%) 65/111 (58.6%) P=0.003
Grade III 125 (40.5%) 96/125 (76.8%)
Intraductal 6 (1.9%) 1/5 (20.0%)
Medullary 7 (2.3%) 5/7 (71.4%)
Papillary 3 (1.0%) 2/3 (66.7%)
Cribriform 3 (1.0%) 1/3 (33.3%)
Mucinous 9 (2.9%) 3/9 (33.3%)
Lobular 4 (1.3%) 1/4 (25.0%)
Oestrogen receptor:
Positive 222 (72.5%) 133/222 (59.6%) X2=4.24
Negative 84 (27.5%) 61/84 (72.6%) P=0.04
Progesterone receptor:
Positive 209 (68.3%) 119/209 (56.9%) X2 = 11.86
Negative 97 (31.7%) 75/97 (77.3%) P=0.0006
less significant relationship was also observed between DNA
aneuploidy and age of patient (P=0.02), advanced nodal
status (P=0.02) and lack of oestrogen receptors (P=0.04).
There was only a weak relation between DNA ploidy and
primary tumour size, stage of disease and postmenopausal
state. Tumours from patients presenting with distant
metastases were frequently DNA-aneuploid.
Survival of patients with operable stage I-III breast cancer
was significantly longer if the tumours were DNA-diploid as
compared to DNA-aneuploid (Figure 1). Patients with
tumours containing multiple aneuploid stemlines had
survival similar to that of patients with single aneuploid
stemlines (data not shown). There were only 20 tumours
with a hypertetraploid DNA content, but these tumours
were associated with a significantly worse prognosis in
comparison with other DNA-aneuploid tumours (Figure 2).
On the other hand, a tetraploid DNA content tended to be
associated with a relatively favourable prognosis.
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Figure 1 Survival of stage 1-111 breast cancer patients (n=297)
according to DNA ploidy (D=DNA-diploid, A =DNA-
aneuploid, P<0.0001). The number of patients at risk at the
beginning of each year is indicated.
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Figure 2 Survival of stage I-III breast cancer patients (n=297)
according to tumour DNA index (DI). Significance of trend in
survival probability: P<0.0001. The numbers at the end of each
curve indicate the number ofpatients still at risk.
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Table II The relation of DNA ploidy and survival in patients with (Stage I-III) primary breast cancer
stratified according to menopausal state, nodal status, primary tumour size, stage, steroid receptor
status and histology
5-year survival 8-year survival Significancea
Diploid Aneuploid Diploid Aneuploid Pi P2
All patients 88.6 60.0 74.3 51.2 0.0001 0.0001
Premenopausal 90.8 58.9 81.8 58.9 0.001 0.004
Postmenopausal 87.1 60.7 67.2 44.8 0.0004 0.0004
Node-negative 94.2 71.0 82.5 62.8 0.0005 0.001
Node-positive 77.9 49.2 55.4 40.4 0.005 0.01
T1 92.3 75.7 83.9 72.1 0.03 0.07
T2 93.2 61.1 74.6 54.1 0.0001 0.0003
T3 75.2 30.8 64.5 30.8 0.06 0.05
T4 51.4 53.4 51.4 17.8 0.8 0.7
Stage I 95.8 80.2 83.9 72.9 0.04 0.08
Stage II 91.4 63.5 82.6 57.5 0.0003 0.0005
Stage III 72.8 37.1 40.0 26.6 0.03 0.04
Ductal infiltrating
Grade I 100.0 100.0 100.0 73.1 0.15 0.14
Grade II 95.4 64.0 72.9 51.0 0.0001 0.0006
Grade III 66.1 50.8 48.6 49.1 0.3 0.5
Other tumours 94.1 44.0 94.1 44.0 0.001 0.001
ER-positive 92.4 66.2 90.5 53.4 0.0001 0.0001
ER-negative 68.4 50.6 53.3 50.6 0.7 0.7
PR-positive 91.5 70.4 77.0 55.2 0.0001 0.0002
PR-negative 77.0 44.1 63.2 44.1 0.05 0.06
aThe significance of the difference in survival is given according to a Wilcoxon-Breslow test (Pl),
which gives greater weight to early observations and according to a Mantel-Cox test (P2), which gives
equal weight to all observations.
Stratification of patients into subgroups defined by other
prognostic factors indicated that DNA aneuploidy was an
equally strong prognostic indicator in premenopausal and
postmenopausal patients as well as in node-negative and
node-positive patients (Table II). DNA aneuploidy was
associated with survival even in patients with small node-
negative primary tumours (stage I), although differences in
survival were less significant due to small numbers of
patients. Among the infiltrating ductal carcinomas an
association between DNA ploidy and survival was most
evident in grade II tumours (Table II). In patients with other
histological tumour types, which were analysed in a single
group, DNA aneuploidy was associated with a significantly
shorter survival as compared to DNA diploidy. The
prognostic value of DNA aneuploidy was evident primarily
in oestrogen and progesterone receptor positive tumours
(Table II).
Survival analysis with covariates was done according to
the Cox model for all stage I-III breast cancer patients for
whom complete data on all variables were available (297
cases) (Table III). DNA ploidy, size of the primary tumour,
nodal involvement and progesterone receptor status were all
independently related to prognosis. In contrast, age of the
patient, menopausal and oestrogen receptor status failed to
show any independent prognostic effect. Surgery and
radiotherapy were given in an almost uniform manner to
patients with similar stage, and the type of treatment had no
independent prognostic value if included in the Cox model.
Forty-eight patients were treated with adjuvant CMF
therapy. If these patients were excluded from the Cox
regression analysis, the results remained unchanged.
When only ductal carcinomas were examined and the
histological grade of tumour was included in a Cox model,
grade (P=0.0001) and DNA ploidy (P=0.03) were both
independently related to survival, as were primary tumour
size (P=0.0003), nodal involvement (P=0.05) and
progesterone receptor status (P=0.003). Tumours with grade
I and diploid DNA content had a 100% 8-year survival rate
(Table II).
Discussion
The 8-year survival rate was significantly better in breast
cancer patients with DNA-diploid as compared to DNA-
aneuploid tumours. This is in accordance with previous
reports on the relation of DNA ploidy with the relapse-free
interval (Hedley et al., 1983; Cornelisse et al., 1987; Dowle et
al., 1987; Kallioniemi et al., 1987a) and overall survival
(Coulson et al., 1984; Cornelisse et al., 1987; Dowle et al.,
1987) in breast cancer. However, in one study (Klintenberg
et al., 1986) no survival difference between DNA-aneuploid
and DNA-diploid breast cancers was observed. Contra-
dictory results regarding the prognostic value of DNA ploidy
analysis may be due to differences in the type of treatment
given to the patients as well as due to methodological
differences causing variation in the proportion of aneuploid
cases detected. Long-term follow-up studies with micro-
spectrophotometric DNA measurements (Atkin, 1972; Auer
et al., 1980; Auer et al., 1984; Fallenius, 1986) support the
prognostic value of DNA ploidy.
Tumours with a hypertetraploid DNA content (DNA
index >2.20) were related to a worse, and those with a
tetraploid DNA content to a better prognosis, than other
DNA-aneuploid tumours. Similar results have been reported
by static cytophotometry in breast cancer (Auer et al., 1980;
Auer et al., 1984; Fallenius, 1986). Our flow cytometric
results in ovarian cancer (Kallioniemi et al., 1987b) also
indicate that hypertetraploid tumours are highly malignant.
In the statistical analyses we treated the DNA-aneuploid
tumours as a single group because only 20 tumours
contained a hypertetraploid cell clone. A multiploid DNA
abnormality did not indicate a worse prognosis than single
DNA aneuploidy, which is consistent with the results of
Cornelisse et al. (1987).
DNA ploidy was not significantly related to menopausal
status, which is in accordance with most previous
publications (Raber et al., 1982; Ewers et al., 1984; Hedley et
al., 1984; Kute et al., 1985). A few investigators have
reported a slightly higher occurrence of DNA-aneuploid640 O.-P. KALLIONIEMI et al.
Table III Univariate and multivariate (Cox model) survival analysis in 297 Stage
I-III breast cancer patients. Relative risk of death, its 95% confidence interval and
P value are given for each covariate
Univariate analyses Multivariate analyses
Relative risk Relative risk
Variable ofdeath P value ofdeath P value
Independently associated with survival:
DNA ploidy:
Diploid 1.0 1.0
Aneuploid 3.0 (1.8, 5.0) <0.0001 2.2 (1.3, 3.8) 0.001
Primary tumour size:
Ti 1.0 1.0
T2 1.7 (0.9, 3.1) <0.0001 1.7 (0.9, 3.1) 0.0007
T3-4 4.3 (2.3, 7.9) 3.4 (1.7, 6.7)
Nodal status:
NO 1.0 1.0
Ni 2.4 (1.6, 3.7) <0.0001 1.9 (1.2, 3.0) 0.04
N2-3 3.7 (1.9, 7.4) 1.8 (0.7, 4.2)
Progesterone receptor:
> 100 1.0 1.0
5-100 1.7 (1.1, 2.5) <0.0001 1.7 (1.0, 2.5) 0.0008
<5 3.3 (1.7, 5.0) 2.5 (1.4, 5.0)
Associated with survival only when analysed alone:
Oestrogen receptor:
> 100 1.0
5-100 1.7 (1.1, 2.5) 0.02 0.5
<5 2.0 (1.1, 3.3) (NS)
Not significantly associated with survival:
Age:
<50 1.0
50-65 1.4 (0.8, 2.2) 0.2 0.1
>65 1.3 (0.8, 2.2) (NS) (NS)
Menopausal status:
Premenop. 1.0
Postmenop. 1.3 (0.9, 2.0) 0.2 0.2
(NS) (NS)
tumours in postmenopausal patients (Thorud et al., 1986;
Dowle et al., 1987). Our results indicated that DNA-
aneuploid tumours were most common in patients aged
50-65. DNA aneuploidy was significantly more common
in node-positive than in node-negative tumours and most
common in tumours with extensive (N2-N3) nodal
involvement, whereas there was no significant correlation
between DNA aneuploidy and primary tumour size. Previous
literature on the relation of DNA ploidy to TNM
classification is controversial. It has been reported that DNA
aneuploidy is related to nodal involvement only (Hedley et
al., 1984), to primary tumour size only (Ewers et al., 1984;
Fallenius et al., 1986; Thorud et al., 1986; Dowle et al.,
1987), to both parameters (Cornelisse et al., 1987) or to
neither of them (Taylor et al., 1983; McDivitt et al., 1986;
Jakobsen et al., 1984).
The present as well as several previous studies clearly
document that poorly differentiated tumours are more often
aneuploid than moderately or well-differentiated ones
(Olszewski et al., 1981; Moran et al., 1984; Jakobsen et al.,
1984; McDivitt et al., 1986; Thorud et al., 1986; Dowle et
al., 1987; Kallioniemi et al., 1987a). The present study and
many (Olszewski et al., 1981; Bichel et al., 1982; Moran et
al., 1984; Coulson et al., 1984; Jakobsen et al., 1984;
Horsfall et al., 1986; Cornelisse et al., 1987; Kallioniemi et
al., 1987a) but not all other studies (Raber et al., 1982;
Taylor et al., 1983; Hedley et al., 1984; McDivitt et al., 1986;
Klintenberg et al., 1986) suggest that DNA aneuploidy is
more common in oestrogen receptor negative than in
receptor positive tumours. We also observed a highly
significant association between DNA aneuploidy and
absence of PR receptors, confirming some previous studies
(Moran et al., 1984; Coulson et al., 1984; Horsfall et al.,
1986; Kallioniemi et al., 1987a) yet again disagreeing with
some others (Taylor et al., 1983; Jakobsen et al., 1984;
McDivitt et al., 1986). Because many of the early studies
were based on relatively few patients, a significant
association between DNA ploidy and the clinicopathological
parameters was not always achieved despite a trend in that
direction.
According to our results DNA ploidy had prognostic
significance in both pre- and postmenopausal patients, in
node-negative and node-positive patients, as well as in
primary tumours of all sizes. The results of Cornelisse et al.
(1987) indicated a less powerful prognostic effect confined
mainly to postmenopausal patients with locally advanced
disease. Hedley et al. (1984) reported that in stage II breast
cancer DNA aneuploidy was related to poor prognosis
irrespective of the number of affected lymph-nodes. Our
results also indicated that oestrogen and especially
progesterone receptor negative tumours were associated with
a low survival rate irrespective of the DNA ploidy level,
whereas in receptor positive tumours DNA ploidy had
significant prognostic influence. This suggests that DNA
aneuploidy might help to identify those patients with steroid
receptor positive tumours, who are unlikely to benefit from
endocrine therapy. Although DNA aneuploidy per se does
not appear to correlate with responsiveness to endocrine
therapy (Stuart-Harris et al., 1985), it has been proposed
(Bichel et al., 1982; Horsfall et al., 1986) that DNA-
aneuploid steroid receptor positive tumours would have a
poor response to endocrine therapy.
A Cox regression analysis showed that DNA aneuploidy,
tumour size, lymph node and progesterone receptor status
were the only independent prognostic factors in breast
cancer. Although the axillary node involvement was in allDNA PLOIDY IN BREAST CANCER 641
cases verified by a pathologist, the extent of the involvement
was determined primarily by clinical examination using the
TNM classification. This may explain why nodal status had
rather weak prognostic effect in multivariate analyses as
compared to e.g. primary tumour size. However, it is
unlikely that this would have affected the prognostic impact
of DNA ploidy, since DNA ploidy had more prognostic
significance in node-negative than in node-positive cases. The
multivariate analyses clearly showed that the content of
progesterone receptors was a better prognostic indicator than
that of oestrogen receptors. The combined analysis of
progesterone receptor content and DNA ploidy seems to
give the most accurate measure of the biological malignancy
of breast tumours. If histological grade was included in the
Cox model, both grade and DNA ploidy showed independent
prognostic significance. It has been definitely demonstrated
that the histological grade of breast cancer is an important
prognostic indicator (Davis et al., 1986; Sharkey, 1982), but
its clinical use has been questioned due to the subjectivity
and interindividual variability (Stenkvist et al., 1979; Davis
et al., 1986; Sharkey, 1982) of visual grading. The analysis of
DNA ploidy is more objective than the evaluation of grade.
Furthermore, the present results indicate that the two
parameters complement each other in the prediction of
aggressiveness of breast cancer.
Our own previous results (Kallioniemi et al., 1987a) as
well as those of Dowle et al. (1987) and Cornelisse et al.
(1987) have shown that differences in the disease-free
survival between DNA-diploid and DNA-aneuploid breast
tumours are greater than those in overall survival. Dowle
and Cornelisse have also reported that differences in survival
between the two ploidy groups decreased after 6-7 years
follow-up. In the present study we observed a constantly
improved survival in patients with DNA-diploid tumours up
to 8 years postoperatively. However, the follow-up period
should be further extended, because deaths due to breast
cancer are noted up to 20 years after initial diagnosis
(Sutherland & Mather, 1986; Harris & Hellman, 1986). The
association between DNA aneuploidy and high S-phase
fraction (Kallioniemi et al., 1987a) could explain why the
survival difference between DNA-diploid and DNA-
aneuploid tumours is most prominent after short-term
follow-up.
In conclusion, our results indicate that DNA ploidy is an
independent prognostic factor in breast cancer. The
combination of DNA ploidy and the content of progesterone
receptors offers the best estimate of the biological
malignancy of cancer cells, which supplements the
information obtained from the TNM classification as well as
the histological grading. It remains to be determined how
DNA ploidy is related to the responsiveness of a steroid
receptor positive breast cancer to endocrine therapy and
what is the prognostic value of DNA ploidy after very long
follow-up times.
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